Sarah Craig | December 9, 2016
Alex Perkins, PhD, Eck Family Assistant Professor in the Department of Biological Sciences, and a member of the Eck Institute for Global Health, along with Guido Espana who holds a postdoctoral position in the Perkins laboratory, were recently published in the journal PLoS Medicine. The results of their study are important contributions to the evidence base that led the World Health Organization (WHO) to form their policy position on the only currently available dengue vaccine.
According to the lead author, Stefan Flasche from the London School of Hygiene & Tropical Medicine, UK, the first available dengue vaccine, CYD-TDV(Dengvaxia), is estimated to reduce the burden of dengue and be potentially cost effective in settings where infections with dengue are common. Perkins notes, “this is an important discovery that suggests to the WHO that a one-size-fits-all policy recommendation for use of the Dengvaxia vaccine is not advisable.”
The international team reported on predictions from eight independent dynamic modeling groups including long-term safety, public health impact, and cost-effectiveness of routine vaccination with Dengvaxia in a range of transmission settings.
Supporting the research component at Notre Dame was the University’s Center for Research Computing where computational resources, such as compute cores to run models, data storage, and the High Performance Computing user support team, are available for Notre Dame faculty, staff and students to utilize to advance their research.